Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Lindsey E. Roeker et al.|Blood|2020Cited by 318
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, Jennifer A. Woyach et al.|New England Journal of Medicine|2023Cited by 213
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L. Crombie, Michael Dickinson, Alex F. Herrera et al.|Blood|2024Cited by 132
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael Wang, Nirav N. Shah, Wojciech Jurczak et al.|Journal of Clinical Oncology|2023Cited by 106
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphomaGeoffrey Shouse, Alexey V. Danilov, Andy Kaempf et al.|Blood Advances|2023Cited by 49